

Alice Huertas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1698903/alice-huertas-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

2,367
citations

25
h-index

48
g-index

48
ext. papers

2,958
ext. citations

7.8
avg. IF

4.85
L-index

#	Paper	IF	Citations
44	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2021 , 117, 1391-1401	9.9	5
43	The Thousand Faces of Leptin in the Lung. <i>Chest</i> , 2021 , 159, 239-248	5.3	7
42	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension: Implications for Therapy. <i>Chest</i> , 2021 ,	5.3	4
41	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	6
40	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 766-782	9.4	27
39	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. <i>Cardiovascular Research</i> , 2020 , 116, 885-893	9.9	35
38	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. <i>Cardiovascular Research</i> , 2020 , 116, 686-697	9.9	25
37	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. <i>FASEB Journal</i> , 2019 , 33, 3670-3679	0.9	14
36	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2019 , 124, 846-855	15.7	48
35	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 2725-2736	8.3	14
34	Dasatinib increases endothelial permeability leading to pleural effusion. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	29
33	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	68
32	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1956-1970	15.9	87
31	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	15
30	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2018 , 154, 872-881	5.3	22
29	New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways. <i>Current Opinion in Pulmonary Medicine</i> , 2017 , 23, 377-385	3	11
28	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2016 , 149, 1482-93	5.3	33

27	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3207-18	15.9	144
26	New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. <i>Chest</i> , 2015 , 147, 529-537	5.3	109
25	Leptin signalling system as a target for pulmonary arterial hypertension therapy. <i>European Respiratory Journal</i> , 2015 , 45, 1066-80	13.6	48
24	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 192, 983-97	10.2	108
23	Hematopoietic Stem Cells and Chronic Hypoxia-Induced Pulmonary Vascular Remodelling. <i>Pancreatic Islet Biology</i> , 2015 , 241-256	0.4	
22	Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. <i>Circulation</i> , 2014 , 129, 1332-40	16.7	110
21	Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. <i>Circulation</i> , 2014 , 129, 1586-97	16.7	131
20	Erythrocytes induce proinflammatory endothelial activation in hypoxia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013 , 48, 78-86	5.7	19
19	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. <i>European Respiratory Review</i> , 2013 , 22, 543-51	9.8	126
18	Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 189-96	10.2	42
17	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012 , 40, 895-904	13.6	84
16	A study of magnesium deficiency in human and experimental pulmonary hypertension. <i>Magnesium Research</i> , 2012 , 25, 21-7	1.7	2
15	Platelets induce endothelial tissue factor expression in a mouse model of acid-induced lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012 , 302, L1209-20	5.8	12
14	Circulating fibrocytes and pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012 , 39, 210-213.6	3.6	5
13	A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 666-76	10.2	68
12	Inflammation in pulmonary arterial hypertension. <i>Chest</i> , 2012 , 141, 210-221	5.3	279
11	Pulmonary veno-occlusive disease: advances in clinical management and treatments. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 217-29; quiz 230-1	3.8	33
10	COPD: a multifactorial systemic disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2011 , 5, 217-24	4.9	57

9	C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 116-23	10.2	147
8	Activation of TNFR1 ectodomain shedding by mitochondrial Ca ²⁺ determines the severity of inflammation in mouse lung microvessels. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1986-99	15.9	73
7	Pharmacokinetic evaluation of continuous intravenous epoprostenol. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010 , 6, 1587-98	5.5	14
6	Hemopoietic and angiogenic progenitors in healthy athletes: different responses to endurance and maximal exercise. <i>Journal of Applied Physiology</i> , 2010 , 109, 60-7	3.7	56
5	Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI. <i>Respiratory Physiology and Neurobiology</i> , 2010 , 170, 23-31	2.8	44
4	Red blood cell-induced proinflammatory lung endothelial signaling in hypoxia. <i>FASEB Journal</i> , 2009 , 23, 1023.4	0.9	
3	Airway acid instillation promotes procoagulant lung endothelial mechanisms in mouse. <i>FASEB Journal</i> , 2009 , 23, 1023.5	0.9	
2	Platelets enhance endothelial adhesiveness in high tidal volume ventilation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008 , 39, 569-75	5.7	22
1	Circulating CD34+ cells are decreased in chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 537-8		7